

INDEX

- Acute nephrotoxic nephritis, 85
- Acute lymphatic leukemia, 138
- Acute rejection, 122
- ADCC, 119, 120
- Adjuvants, 62, 63, 128
- Adoptive immunotherapy, 129
- Afferent phase of immune response, 2, 117
- Aleutian disease virus, 103
- ALG, 124
- Allelic exclusion of lymphocytes, 19
- Allografts, 115
- Allotype suppression, 65
- Anaphylaxis, 72
- Antibodies (see also immunoglobulin), 2, 12
 - autoantibodies, 106, 108
 - theories of production of, 12, 13
- Antibody dependent cell-mediated cytotoxicity, 120
- Antibody forming cells, 15
- Antigens, 2, 3,
 - binding of, 23
 - dose of, 63
 - physical form of, 63
 - transplantation, 3, 41, 43, 114
 - tumor-specific, 131
 - viral, 104, 108, 109
- Antigen-antibody complexes:
 - in glomerulonephritis, 73
 - in serum sickness, 72
 - in Arthus reaction, 75, 76
 - in thyroiditis, 76
- Antigen-interaction genes, 47
- Antigraft-antibody, 119
- Antinuclear antibody, 106, 108, 110
- Appendix, 5
- Arthus reaction, 75, 76
- Ataxia telanjectasia, 148, 153
- Autoradiography, 14
- Azothioprine, 123, 148

- B cells, 2, 3, 5, 8, 11, 15, 16, 23, 37, 58, 119
 - maturation of, 24-26
 - memory cells, 38
 - subpopulations of, 38
- Blast transformation, 8
- Bone-marrow, 5
- Bone-marrow derived lymphocytes (see B-cells)
- Burkitt's lymphoma, 148
- Bursa equivalent, 9
- Bursa of Fabricius, 5
 - effect of bursectomy, 16

- C3 receptor, 4, 11
 - immature B cells and, 26
- C-type virus, 102, 103
- Capping, 14, 20-23
- Cell-interaction genes, 44, 47
- Cell-interaction molecule, 47
- Cell surface antigens, 8
- Central phase of immune response, 2
- Chemical mediators in serum sickness, 91
- Chemotactic attraction of polymorphonuclear leukocyte in inflammation, 87
- Chronic lymphatic leukemia, 138
- Chronic rejection, 122
- Collaboration of T and B cells, 3, 4, 15, 44, 46, 52, 54
- Complement, 11, 41, 84, 87, 88
 - in graft immunity, 123
 - in immune complex disease, 76, 84, 87, 92, 105
- Concanavilin A, 8
- Congenital immune deficiency, 136
- Constant region of immunoglobulin molecule, 43
- Cyclophosphamide, 148
- Cytotoxic T lymphocytes, 37, 43, 118

- Delayed-type hypersensitivity, 3, 37, 59, 62

- Effector or efferent phase of immune response, 2, 118
- Endotoxin, 8
- Enhancement of immune responses, 128

- Epstein-Barr virus, 103, 148
- Fc receptors, 11, 17
- "Feedback" regulation, 38, 59, 64
- Fluid mosaic model of plasma membrane, 20
- Gamma globulins, see immunoglobulins
- Genetic control of immune response, 46-49
- Germinal center
 - in lymph nodes, 17
 - in spleen, 17
- Glomerular basement membrane
 - antibody to, 73
- Glomerulonephritis, 81, 105
 - immunopathogenic mechanisms, 81, 82, 93
- Goodpasture's syndrome, 73
- Graft versus host, 4
 - antigens involved in, 44
- Granulocytes, see polymorphonuclear leukocytes
- gut associated lymphoid tissue, 5

- H-2, 8, 43
- HLA, 8, 43, 114
- Heavy chain, 43
- Helper cells, 3, 15, 37, 60, 61, 119
- Histamine, 41
- Histocompatibility antigens, 41
 - human, 8, 43, 114
 - mouse, 8
 - role in graft rejection, 117
- Histocompatibility system, 8, 43, 114
- Hodgkin's disease, 51
- Humoral immunity, 57
- Hyperacute rejection, 121
- Hypersensitivity
 - anaphylaxis, 72
 - Arthus reaction, 75, 76
 - serum sickness, 72, 85

- Ia antigens, 44, 65

- Idotype, 64, 65
- Immediate type sensitivities, see anaphylaxis, Arthus reaction
- Immune adherence, 87
- Immune complexes, see antigen-antibody complexes
- Immune deficiencies
 - ataxia telanejiectasia, 136
 - congenital, 136
 - increased susceptibility to tumors and, 135-142, 147
 - isolated IgM deficiency, 136
 - severe combined, 136
 - Wiskott-Aldrich Syndrome, 136
- Immune RNA, 124
- Immune system
 - afferent phase, 2, 117
 - and aging, 138
 - cell mediated, 3, 4, 57
 - central phase, 2, 35
 - diseases of, 50, 71-93, 136, 148
 - effector or efferent phase, 2, 12
 - genes of, 41, 44-47
 - genetic control of, 46,
 - humoral, 57
 - molecules of, 38, 47
 - regulation of, 44-46, 64
- Immunofluorescence, 13
- Immunoglobulin molecule
 - class, 17-19
 - IgA, 18
 - IgD, 14
 - IgE, 51
 - IgG, 17, 18, 58
 - IgM, 17, 18, 24, 25, 58
 - constant region of, 43
 - heavy chain, 43
 - light chain, 43
 - location of, 6
 - variable region of, 43

- Immunologic adaptation, 124
- Immunosuppression
 - by ALG, 124
 - by drugs, 123, 124
 - by thymectomy, 119, 147,
 - by tumors, 127, 128
 - by X-ray, 3
 - increased susceptibility to tumors and, 148
- Immunotherapy
 - adoptive, 129
 - non specific active, 128
 - passive transfer of informational substances, 131
 - specific active, 130
- Ir genes, 44, 46, 47
- Isografts, 114
- Isolated IgM deficiency, 136

- "Killer" cells, 37, 59, 61, 119

- Leukemia
 - acute lymphatic, 138
 - chronic lymphatic, 138
- Light chain, 43
- Lupus erythematosus, 106, 109
- Ly antigens, 61
- Lymph nodes, 5
- Lymphocytes, 2, 35
- Lymphocytic chorio meningitis (LCM), 104-107, 109
- Lymphoreticular malignancies and
 - aging, 138, 142
 - immunodeficiencies, 136, 147
 - immunosuppression, 138, 147

- Macrophages, 2, 6, 35
 - in graft rejection, 120
- Major histocompatibility complex (MHC), 46, 47, 114
- Malignancy in primary immune deficiency patients, 136, 138, 141
- Measles, 103, 104
- Memory B cells, 38
- Migration inhibition factor (MIF), 41

- Migration of lymphocytes, 62
- Mixed lymphocyte reaction, 37, 114
 - antigens involved in, 44
- Monocytes, 6
- Mouse bone-marrow lymphocyte antigen, 8

- Neoplasms
 - antigens, 131
 - immunity to, 2
 - immunotherapy of, 127-132
- Neuraminidase, 130
- Neutrophil, see polymorphonuclear leukocyte
- Nonspecific active immunotherapy, 128
- Nude mice, 147

- Oncorna virus, 102

- Paracortical region of lymph node, 6
- "Passenger" lymphocytes, 117
- Periarteriolar region of spleen, 6
- Phytohemagglutinin, 8
- Phytomitogens, 8
- Plasma cell, 3, 12, 24, 119
- Plasma cell antigen, 8
- Plasma membrane, 20
- Platelets, role in serum sickness, 91, 92
- Platelet activating factor (PAF), 92
- Polymorphonuclear leukocytes, 74, 76, 81, 84-89
- Polyoma virus, 103, 108
- Polyvinylpyrrolidone (PVP), 58
- Prednisone, 123

- Receptors
 - for antigen, 6, 11
- Red cells as indicator cells, 14
- Redistribution of membrane receptors, 20-23
- Rejection
 - acute, 122
 - antigens involved in, 117
 - cell-mediated nature of, 118

- chronic, 122, 123
 - genetics involved in (mouse), 43
 - hyperacute, 121
 - of tissue grafts, 37, 114
 - of tumors, 37
- Scripp's leukemia virus (SLV), 109
- Secondary lymphoid organs, 5
- Sensitization to allografts, 117, 118
- Serotonin, 41
- Serum sickness, 72, 85
 - experimental, 78-81
- Severe combined immunodeficiency, 136
- "Side Chains", 12
- Specific active immunotherapy, 130
- Spleen, 5
- Stem cells, 5
- Suppressor cells, 3, 37, 47, 52, 60
 - defects of, 49, 51
- Surface immunoglobulin, 15-17, 24, 35
- T1, 60
- T2, 60
- T cells, 2, 3, 5, 8, 11, 15, 37, 61, 118, 119
 - mediators produced by, 41
 - subpopulations of, 37, 60, 61
- Theta antigen, 8
- Thymectomy, effect of, 16, 146, 147
- Thymocytes, 15
- Thymus, 5
- Thymus dependent responses, 59, 60
- Thymus independent responses, 58, 59
- Thymus leukemia antigen, 8, 61
- Thyroiditis, 76
- Tolerance
 - induction of, 25
- Toxin neutralization, 2
- Transplantation
 - antigens, 41, 43, 114
 - four laws of, 114, 115

Tumors, see neoplasms

Tumor associated antigens, 131

Tumor immunity, 2

Variable region of immunoglobulin molecule, 43

Vasoactive amines, 62, 91, 92

VCN, 130

Viruses

 Aleutian, disease, 103

 antiviral-virus complexes, 105

 C-type, 102, 103

 chronic infection by, 102, 104

 Epstein-Barr, 103, 148

 lymphocytic choriomeningitis, 1-4-107, 109

 measle, 103, 104

 oncornavirus, 102, 103

 polyma, 103, 108

 Scripps leukemia, 109

Wisbott-Aldrich Syndrome, 136

X-ray, effects of, 3